Nome |
# |
Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors, file e27ce42c-b4b4-2581-e053-d805fe0acbaa
|
660
|
Management of older patients with multiple myeloma, file e27ce426-d3d7-2581-e053-d805fe0acbaa
|
327
|
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients., file e27ce426-d3d5-2581-e053-d805fe0acbaa
|
282
|
The role of pre-transplant induction regimens and autologous stem cell transplantation in the era of novel targeted agents, file e27ce427-812e-2581-e053-d805fe0acbaa
|
279
|
Nuances in the Management of Older People With Multiple Myeloma, file e27ce42a-e59d-2581-e053-d805fe0acbaa
|
249
|
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma, file e27ce435-5f64-2581-e053-d805fe0acbaa
|
245
|
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project, file e27ce435-7fed-2581-e053-d805fe0acbaa
|
229
|
A Simple Score, Based On Geriatric Assessment, Improves Prediction of Survival, and Risk Of Serious Adverse Events In Elderly Newly Diagnosed Multiple Myeloma Patients, file e27ce42a-ee98-2581-e053-d805fe0acbaa
|
222
|
Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma, file e27ce430-af99-2581-e053-d805fe0acbaa
|
213
|
Trichoderma species fungemia after high-dose chemotherapy and autologous stem cell transplantation: a case report, file e27ce428-b44a-2581-e053-d805fe0acbaa
|
194
|
Autologous Transplantation and Maintenance Therapy in Multiple Myeloma, file e27ce432-dc72-2581-e053-d805fe0acbaa
|
191
|
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results, file e27ce427-86ab-2581-e053-d805fe0acbaa
|
190
|
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial, file e27ce435-9730-2581-e053-d805fe0acbaa
|
180
|
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group, file e27ce42f-8b46-2581-e053-d805fe0acbaa
|
170
|
Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: A meta-analysis, file e27ce42f-8645-2581-e053-d805fe0acbaa
|
163
|
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: Results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study, file e27ce427-7c64-2581-e053-d805fe0acbaa
|
160
|
Therapeutic monoclonal antibodies and antibody products: Current practices and development in multiple myeloma, file e27ce42f-7537-2581-e053-d805fe0acbaa
|
156
|
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma, file e27ce426-f782-2581-e053-d805fe0acbaa
|
153
|
Management of myeloma: an Italian perspective, file e27ce426-ce62-2581-e053-d805fe0acbaa
|
125
|
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials, file e27ce430-fb2b-2581-e053-d805fe0acbaa
|
122
|
Emerging drugs and combinations to treat multiple myeloma, file e27ce430-f3b6-2581-e053-d805fe0acbaa
|
120
|
Lenalidomide maintenance with or without prednisone in newly diagnosed myeloma patients: A pooled analysis, file e27ce430-5f1c-2581-e053-d805fe0acbaa
|
110
|
High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib., file e27ce427-8454-2581-e053-d805fe0acbaa
|
108
|
From transplant to novel cellular therapies in multiple myeloma: EMN guidelines and future perspectives, file e27ce42c-54ed-2581-e053-d805fe0acbaa
|
100
|
Promises and pitfalls in the use of PD-1/PD-L1 inhibitors in multiple myeloma, file e27ce42f-55dd-2581-e053-d805fe0acbaa
|
100
|
Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents, file e27ce430-bd95-2581-e053-d805fe0acbaa
|
100
|
Autologous Transplantation in Elderly Multiple Myeloma Patients: Is the Procedure Cost Effective?, file e27ce427-822a-2581-e053-d805fe0acbaa
|
99
|
Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA), file e27ce42d-5d05-2581-e053-d805fe0acbaa
|
99
|
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis, file e27ce42f-6e99-2581-e053-d805fe0acbaa
|
97
|
European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications, file e27ce427-76e7-2581-e053-d805fe0acbaa
|
96
|
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network, file e27ce431-3459-2581-e053-d805fe0acbaa
|
96
|
Pursuing a curative approach in multiple myeloma: A review of new therapeutic strategies, file e27ce42f-55d7-2581-e053-d805fe0acbaa
|
90
|
Prevention and management of adverse events of novel agents in multiple myeloma: A consensus of the European Myeloma Network, file e27ce42f-6e94-2581-e053-d805fe0acbaa
|
90
|
European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when, file e27ce431-0632-2581-e053-d805fe0acbaa
|
88
|
Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate?, file e27ce42f-55d3-2581-e053-d805fe0acbaa
|
87
|
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN), file e27ce435-99a2-2581-e053-d805fe0acbaa
|
83
|
Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR, file e27ce430-fe9c-2581-e053-d805fe0acbaa
|
81
|
Autologous transplant for myeloma: When the old meets the new, file e27ce42f-90b7-2581-e053-d805fe0acbaa
|
80
|
Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs, file e27ce42f-65c2-2581-e053-d805fe0acbaa
|
79
|
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial, file e27ce431-d84e-2581-e053-d805fe0acbaa
|
72
|
Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma, file e27ce430-925f-2581-e053-d805fe0acbaa
|
70
|
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project, file e27ce435-990a-2581-e053-d805fe0acbaa
|
68
|
Cardiovascular organ damage and blood pressure levels predict adverse events in multiple myeloma patients undergoing carfilzomib therapy, file e27ce42f-a12e-2581-e053-d805fe0acbaa
|
60
|
Stem Cell Transplantation in Multiple Myeloma, file e27ce42f-5d6d-2581-e053-d805fe0acbaa
|
59
|
MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients, file e27ce426-f87f-2581-e053-d805fe0acbaa
|
57
|
Editorial: Exploiting the Immune System to Treat Multiple Myeloma: From Transplantation to Novel Treatment Approaches, file e27ce431-0571-2581-e053-d805fe0acbaa
|
57
|
Multiple myeloma patients undergoing carfilzomib: Development and validation of a risk score for cardiovascular adverse events prediction, file e27ce431-dbd0-2581-e053-d805fe0acbaa
|
52
|
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: A pooled analysis, file e27ce433-b2d9-2581-e053-d805fe0acbaa
|
51
|
Clinical and pharmacologic features of monoclonal antibodies and checkpoint blockade therapy in multiple myeloma, file 185097a3-5f0f-4eca-ba69-26ed618f2ebd
|
49
|
Chromosome 1 abnormalities in newly diagnosed elderly multiple myeloma patients treated with novel therapies., file e27ce426-f477-2581-e053-d805fe0acbaa
|
48
|
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma, file e27ce434-fc96-2581-e053-d805fe0acbaa
|
47
|
Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma, file e27ce431-52f2-2581-e053-d805fe0acbaa
|
46
|
Checkpoint inhibitors and myeloma: promises, deadlocks and new directions, file e27ce431-0ffc-2581-e053-d805fe0acbaa
|
45
|
CyTOF®: A New Tool to Decipher the Immunomodulatory Activity of Daratumumab, file e27ce42e-b74f-2581-e053-d805fe0acbaa
|
41
|
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde, file e27ce432-a6ac-2581-e053-d805fe0acbaa
|
37
|
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration, file e27ce435-4d46-2581-e053-d805fe0acbaa
|
37
|
Treatment of newly diagnosed elderly multiple myeloma, file e27ce435-7ca7-2581-e053-d805fe0acbaa
|
37
|
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension, file a80eb078-016b-45f2-b47c-8f0139cbeb1c
|
34
|
MRD Assessment in Multiple Myeloma: Progress and Challenges, file e27ce435-4a3c-2581-e053-d805fe0acbaa
|
34
|
Plasma cell leukemia: update on biology and therapy, file e27ce435-9d30-2581-e053-d805fe0acbaa
|
34
|
Effects of Carfilzomib Therapy on Left Ventricular Function in Multiple Myeloma Patients, file e27ce431-df1e-2581-e053-d805fe0acbaa
|
30
|
Anti-CD38 monoclonal antibodies in multiple myeloma: another cook in the kitchen?, file e27ce435-8d49-2581-e053-d805fe0acbaa
|
23
|
European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications, file e27ce432-5582-2581-e053-d805fe0acbaa
|
22
|
Moving Toward Continuous Therapy in Multiple Myeloma, file e27ce434-deab-2581-e053-d805fe0acbaa
|
21
|
Novel investigational drugs active as single agents in multiple myeloma, file e27ce435-a456-2581-e053-d805fe0acbaa
|
19
|
Special problems in the management of elderly patients with multiple myeloma, file e27ce435-8ee9-2581-e053-d805fe0acbaa
|
18
|
Redefining the treatment paradigm for multiple myeloma, file e27ce435-985b-2581-e053-d805fe0acbaa
|
16
|
Normalization of the Immunological Microenvironment and Sustained Minimal Residual Disease Negativity: Do We Need Both for Long-Term Control of Multiple Myeloma?, file 6e5a9826-b309-4ba1-b726-579d798b45ad
|
15
|
From transplant to novel cellular therapies in multiple myeloma: EMN guidelines and future perspectives, file e27ce42f-74db-2581-e053-d805fe0acbaa
|
14
|
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing, file e27ce435-6515-2581-e053-d805fe0acbaa
|
14
|
Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials, file e27ce435-88a9-2581-e053-d805fe0acbaa
|
14
|
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing, file a4e97a93-3d82-4aaa-b92d-85fef843542e
|
12
|
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials, file e27ce435-4971-2581-e053-d805fe0acbaa
|
12
|
European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications, file e27ce428-a199-2581-e053-d805fe0acbaa
|
11
|
Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma, file e27ce435-8204-2581-e053-d805fe0acbaa
|
11
|
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis, file c232163f-5136-48e3-926e-a6f057e605e6
|
10
|
Clinical and pharmacologic features of monoclonal antibodies and checkpoint blockade therapy in multiple myeloma, file e27ce435-4081-2581-e053-d805fe0acbaa
|
10
|
Antibody-drug conjugates: when chemotherapy meets immuno-oncology, file e27ce435-7fcc-2581-e053-d805fe0acbaa
|
9
|
CyTOF®: A New Tool to Decipher the Immunomodulatory Activity of Daratumumab, file e27ce435-8fab-2581-e053-d805fe0acbaa
|
9
|
CD38 as an immunotherapeutic target in multiple myeloma, file e27ce435-a5c4-2581-e053-d805fe0acbaa
|
9
|
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis, file e27ce435-866b-2581-e053-d805fe0acbaa
|
8
|
Multiple myeloma with t(11;14): unique biology and evolving landscape, file 55ead21a-32e1-46f1-be01-56413a9b4d6e
|
7
|
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing, file e27ce431-1142-2581-e053-d805fe0acbaa
|
7
|
Novel investigational drugs active as single agents in multiple myeloma, file e27ce431-2880-2581-e053-d805fe0acbaa
|
7
|
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials, file e27ce42f-5419-2581-e053-d805fe0acbaa
|
6
|
CD38 as an immunotherapeutic target in multiple myeloma, file e27ce42f-83d9-2581-e053-d805fe0acbaa
|
6
|
Plasma cell leukemia: update on biology and therapy, file e27ce431-f436-2581-e053-d805fe0acbaa
|
6
|
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing, file ab42bacd-9a56-40a8-a10a-b605c8f38e7e
|
5
|
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: A pooled analysis, file e27ce42f-a041-2581-e053-d805fe0acbaa
|
5
|
The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma, file e27ce431-dbd1-2581-e053-d805fe0acbaa
|
5
|
Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options, file e27ce432-0f4b-2581-e053-d805fe0acbaa
|
5
|
Clinical and pharmacologic features of monoclonal antibodies and checkpoint blockade therapy in multiple myeloma, file e27ce432-2dad-2581-e053-d805fe0acbaa
|
5
|
Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients, file e27ce435-4549-2581-e053-d805fe0acbaa
|
5
|
Treatment of newly diagnosed elderly multiple myeloma, file e27ce435-7b03-2581-e053-d805fe0acbaa
|
5
|
Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma, file 46ef473b-1772-4ecc-a7cd-5c487348f742
|
4
|
MRD Assessment in Multiple Myeloma: Progress and Challenges, file e27ce431-ec0c-2581-e053-d805fe0acbaa
|
4
|
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial, file 64fe7309-43af-4f49-aab3-bcfc7e8ba23f
|
3
|
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma, file 80dfff5e-cb36-4f94-a39f-23ec8780c2cd
|
3
|
European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias, file e27ce42f-6ea3-2581-e053-d805fe0acbaa
|
3
|
Melphalan and its role in the management of patients with multiple myeloma, file e27ce431-e0d0-2581-e053-d805fe0acbaa
|
3
|
Totale |
7.749 |